C07K2319/33 - page 7 - CPC Classification Index

#1801

20170340714

2017-11-30

Compositions for treating pathological calcification conditions, and methods using same

#1802

20170340713

2017-11-30

Compositions for treating pathological calcification conditions, and methods using same

#1803

20170340672

2017-11-30

Chimeric antigen receptor and methods of use thereof

#1804

20170336393

2017-11-23

Methods for making novel antigen binding domains

#1805

20170335311

2017-11-23

CHIMERIC PROTEIN

#1806

20170335010

2017-11-23

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

#1807

20170335009

2017-11-23

TETRAVALENT TLR9 BISPECIFIC ANTIBODY

#1808

20170334996

2017-11-23

FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES

#1809

20170333521

2017-11-23

METHOD FOR TARGETED INTRAPROSTATIC ADMINISTRATION OF PRX302 FOR TREATMENT OF PROSTATE CANCER

#1810

20170333481

2017-11-23

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

#1811

20170333480

2017-11-23

GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS

#1812

20170327591

2017-11-16

Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand

#1813

20170327562

2017-11-16

Designer collagens and use thereof

#1814

20170327553

2017-11-16

COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS

#1815

20170326179

2017-11-16

Compositions and methods for inhibition of lineage specific antigens

#1816

20170320941

2017-11-09

CS1-specific chimeric antigen receptor engineered immune effector cells

#1817

20170320933

2017-11-09

Cytokine-based fusion proteins for treatment of immune disorders

#1818

20170318817

2017-11-09

Phage derived antimicrobial activities

#1819

20170306043

2017-10-26

Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof

#1820

20170306030

2017-10-26

CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF

#1821

20170305989

2017-10-26

IL22 immunoconjugates

#1822

20170305987

2017-10-26

Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof

#1823

20170298364

2017-10-19

Fusion protein, nanoparticle composed of a plurality of monomers of said fusion protein, and uses thereof

#1824

20170298106

2017-10-19

Multivalent and monovalent multispecific complexes and their uses

#1825

20170296678

2017-10-19

Methods and compositions for transducing lymphocytes and regulated expansion thereof

#1826

20170296640

2017-10-19

Peptides and combination of peptides for use in immunotherapy against NHL and other cancers

#1827

20170283504

2017-10-05

BCMA binding molecules and methods of use thereof

#1828

20170283500

2017-10-05

Chimeric receptors and methods of use thereof

#1829

20170283497

2017-10-05

ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy

#1830

20170283490

2017-10-05

Nanobodies suitable for neuron regeneration therapy

#1831

20170283489

2017-10-05

Chimeric antigen receptor specific for SSEA4 antigen

#1832

20170283471

2017-10-05

MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS

#1833

20170281787

2017-10-05

CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN

#1834

20170281766

2017-10-05

Chimeric antigen and T cell receptors and methods of use

#1835

20170275374

2017-09-28

Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy

#1836

20170275362

2017-09-28

Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof

#1837

20170274044

2017-09-28

Fusion protein comprising albumin and retinol-binding protein

#1838

20170274025

2017-09-28

Oncolytic HSV vector

#1839

20170267756

2017-09-21

Tagged chimeric effector molecules and receptors thereof

#1840

20170267742

2017-09-21

Transgene genetic tags and methods of use

#1841

20170267739

2017-09-21

Chimeric antigen receptors to control HIV infection

#1842

20170260517

2017-09-14

Cell-targeted cytotoxic constructs

#1843

20170260274

2017-09-14

Construct for the delivery of a molecule into the cytoplasm of a cell

#1844

20170260246

2017-09-14

CARCINOMA HOMING PEPTIDE (CHP), ITS ANALOGS, AND METHODS OF USING

#1845

20170247672

2017-08-31

Method for efficient delivery of therapeutic molecules in vitro and in vivo

#1846

20170247417

2017-08-31

T-cell redirecting bispecific antibodies for treatment of disease

#1847

20170246279

2017-08-31

Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

#1848

20170246277

2017-08-31

Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells

#1849

20170240885

2017-08-24

Selective recovery

#1850

20170240612

2017-08-24

Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

#1851

20170240608

2017-08-24

Cleavage-activatable interferon-alpha proprotein

#1852

20170240596

2017-08-24

Prostate-specific membrane antigen (PSMA) targeting peptides

#1853

20170233747

2017-08-17

Targeted/TGF-ßRII fusion proteins and methods for making same

#1854

20170233449

2017-08-17

Fusions of antibodies to CD38 and attenuated interferon alpha

#1855

20170226183

2017-08-10

ROR1 specific multi-chain chimeric antigen receptor

#1856

20170226161

2017-08-10

Modified meningococcal fHbp polypeptides

#1857

20170218074

2017-08-03

Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies

#1858

20170211076

2017-07-27

FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME

#1859

20170210811

2017-07-27

Chimeric antigen receptors targeting epidermal growth factor receptor variant III

#1860

20170204372

2017-07-20

Engineered cells for adoptive cell therapy

#1861

20170204144

2017-07-20

Selective recovery

#1862

20170202962

2017-07-20

Combination of lenalidomide and polypeptide construct, and uses thereof

#1863

20170183418

2017-06-29

BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

#1864

20170183415

2017-06-29

Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

#1865

20170182147

2017-06-29

CD40 ligand fusion protein vaccine

#1866

20170174777

2017-06-22

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

#1867

20170173080

2017-06-22

Targeted disruption of the MHC cell receptor

#1868

20170152297

2017-06-01

Drug regulated transgene expression

#1869

20170151342

2017-06-01

Targeted interferons demonstrate potent apoptotic and anti-tumor activities

#1870

20170145063

2017-05-25

Modified biotin, streptavidin mutant, and usage of them

#1871

20170143765

2017-05-25

Chimeric antigen receptor and methods of use thereof

#1872

20170137783

2017-05-18

Methods for improving the efficacy and expansion of immune cells

#1873

20170137493

2017-05-18

Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing

#1874

20170137484

2017-05-18

Methods for cancer therapy using mutant light molecules with increased affinity to receptors

#1875

20170137465

2017-05-18

C6S specific transporter molecules

#1876

20170129967

2017-05-11

CAR-expressing NK-92 cells as cell therapeutic agents

#1877

20170121379

2017-05-04

USING B-CELL-TARGETING ANTIGEN IGG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES

#1878

20170114123

2017-04-27

Anti-alpha-synuclein antibodies and methods of use

#1879

20170114094

2017-04-27

Keratan sulfate specific transporter molecules

#1880

20170107286

2017-04-20

Chimeric antigen receptors targeting CD-19

#1881

20170101636

2017-04-13

Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties

#1882

20170096684

2017-04-06

Lentiviral vectors

#1883

20170096469

2017-04-06

Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue

#1884

20170095581

2017-04-06

Bispecific peptide conjugate and radioactive bispecific peptide imaging agent

#1885

20170088631

2017-03-30

Immunoconjugates

#1886

20170088599

2017-03-30

High affinity NY-ESO T cell receptors

#1887

20170088595

2017-03-30

Lectin compositions and methods for modulating an immune response to an antigen

#1888

20170087246

2017-03-30

Modular antigen transportation molecules and uses thereof in animals

#1889

20170081412

2017-03-23

Antibody-fynomer conjugates

#1890

20170081411

2017-03-23

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

#1891

20170081373

2017-03-23

Targeting of chondroitin sulfate glycans

#1892

20170081370

2017-03-23

Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302

#1893

20170080104

2017-03-23

Cell surface coupling of nanoparticles

#1894

20170080101

2017-03-23

Transduction

#1895

20170080060

2017-03-23

Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide

#1896

20170073388

2017-03-16

Engineered antibody-interferon mutant fusion molecules

#1897

20170073382

2017-03-16

Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells

#1898

20170066825

2017-03-09

Erythrocyte-binding therapeutics

#1899

20170056518

2017-03-02

Pharmaceuticals in joint-linker configurations for treating pathological blood clots

#1900

20170051071

2017-02-23

Monovalent blood brain barrier shuttle modules

#1901

20170051042

2017-02-23

Targeted coagulation factors and method of using the same

#1902

20170044512

2017-02-16

Chimeric clotting factors

#1903

20170044269

2017-02-16

ADENOVIRAL TARGETING, COMPOSITIONS AND METHODS THEREFOR

#1904

20170044227

2017-02-16

Interleukin 15 as selectable marker for gene transfer in lymphocytes

#1905

20170035819

2017-02-09

Oncolytic HSV vector

#1906

20170029470

2017-02-02

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses

#1907

20170022274

2017-01-26

T-cell redirecting bispecific antibodies for treatment of disease

#1908

20170022263

2017-01-26

Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor

#1909

20170016905

2017-01-19

Targeting of chondroitin sulfate glycans

#1910

20170015726

2017-01-19

TARGETED THERAPEUTICS

#1911

20170015721

2017-01-19

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

#1912

20170014495

2017-01-19

ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF

#1913

20170008947

2017-01-12

Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer

#1914

20170007680

2017-01-12

Lysosomal Targeting Peptides and Uses Thereof

#1915

20170000898

2017-01-05

Therapeutic biologic for treatment of hepatocellular carcinoma

#1916

20160376323

2016-12-29

Adeno-associated virus virions with variant capsid and methods of use thereof

#1917

20160375151

2016-12-29

Adeno-associated virus virions with variant capsid and methods of use thereof

#1918

20160367635

2016-12-22

IL-15 variants and uses thereof

#1919

20160362500

2016-12-15

Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes

#1920

20160362469

2016-12-15

Methods for protein modification in pharmaceutical applications

#1921

20160362458

2016-12-15

Modified microbial toxin receptor for delivering agents into cells

#1922

20160361431

2016-12-15

Methods for reducing immune responses

#1923

20160361429

2016-12-15

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

#1924

20160355593

2016-12-08

ANTIBODY VACCINE CONJUGATES AND USES THEREFOR

#1925

20160355590

2016-12-08

Lym-1 and Lym-2 targeted CAR cell immunotherapy

#1926

20160354484

2016-12-08

Compositions for inducing antigen-specific tolerance

#1927

20160354454

2016-12-08

Methods for induction of antigen-specific immune tolerance

#1928

20160354453

2016-12-08

Compositions for generating immune tolerance by targeting erythrocytes

#1929

20160347854

2016-12-01

Anti-TOSO chimeric antigen receptor and its use

#1930

20160347835

2016-12-01

METHOD OF INHIBITING METASTASIS OF CANCER CELLS AND MODULATING AUTOIMMUNE DISEASES USING GAL-3BP-Fc FUSION PROTEIN

#1931

20160347806

2016-12-01

OLIGOMERIZATION DOMAIN OF P53 TO BYPASS THE DOMINANT-NEGATIVE EFFECT OF MUTANT

#1932

20160347798

2016-12-01

MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES AND CELL-TARGETED MOLECULES FOR DIRECT CELL KILLING AND IMMUNE STIMULATION VIA MHC CLASS I PRESENTATION AND METHODS REGARDING THE SAME

#1933

20160346365

2016-12-01

Factor IX polypeptides and methods of use thereof

#1934

20160340649

2016-11-24

Costimulatory chimeric antigen receptor T cells targeting IL13Rα2

#1935

20160340442

2016-11-24

Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

#1936

20160340435

2016-11-24

Molecular constructs for treating central nervous system diseases

#1937

20160340427

2016-11-24

Molecular constructs for treating infectious diseases

#1938

20160340409

2016-11-24

Compositions and methods for treatment of hematological malignancies

#1939

20160340405

2016-11-24

Methods and compositions for protection against lentiviral infections

#1940

20160340394

2016-11-24

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

#1941

20160339116

2016-11-24

Molecular constructs with targeting and effector moieties for treating infectious diseases

#1942

20160339115

2016-11-24

Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod

#1943

20160339111

2016-11-24

Peptide core-based multi-arm linkers for treating infectious diseases

#1944

20160339110

2016-11-24

Peptide core-based multi-arm linkers for treating central nervous system diseases

#1945

20160339109

2016-11-24

Peptide core-based multi-arm linkers and their applications

#1946

20160333374

2016-11-17

Pseudotyped lentiviral vectors

#1947

20160331821

2016-11-17

Vaccines for treatment and prevention of cancer

#1948

20160318986

2016-11-03

IL-15 and IL-15R\alpha sushi domain based immunocytokines

#1949

20160312207

2016-10-27

R-SPONDIN ANTAGONISTS AND METHODS OF TREATING CANCER ASSOCIATED WITH ABERRANT ACTIVATION OF WNT SIGNALING

#1950

20160311915

2016-10-27

Bi-specific T-cell engager specific for BCMA

#1951

20160311910

2016-10-27

Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

#1952

20160311884

2016-10-27

EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3

#1953

20160311877

2016-10-27

CRP capture/detection of gram positive bacteria

#1954

20160310609

2016-10-27

Compositions and methods for delivering inhibitory oligonucleotides

#1955

20160304619

2016-10-20

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

#1956

20160304617

2016-10-20

5T4-TARGETED IMMUNOFUSION MOLECULE AND METHODS

#1957

20160297884

2016-10-13

Chimeric antigen receptors targeting B-cell maturation antigen

#1958

20160297868

2016-10-13

Composition and method for therapeutic agent delivery during pregnancy

#1959

20160297863

2016-10-13

EPHA3 And multi-valent targeting of tumors

#1960

20160296609

2016-10-13

DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE SCLEROSIS

#1961

20160289296

2016-10-06

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

#1962

20160287687

2016-10-06

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

#1963

20160280798

2016-09-29

ALK ANTIBODIES, CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND THEIR USE

#1964

20160279208

2016-09-29

Method for suppressing spasmodic torticollis

#1965

20160272710

2016-09-22

Targeting tissue factor to activated platelets

#1966

20160264665

2016-09-15

Binding-triggered transcriptional switches and methods of use thereof

#1967

20160263240

2016-09-15

Immunoconjugates

#1968

20160257943

2016-09-08

Factor IX polypeptides and methods of use thereof

#1969

20160251409

2016-09-01

Targeted Delivery of Factor VIII Proteins to Platelets

#1970

20160250267

2016-09-01

Oncolytic HSV vector

#1971

20160243206

2016-08-25

Factor IX polypeptides and methods of use thereof

#1972

20160237156

2016-08-18

IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF

#1973

20160237155

2016-08-18

Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins

#1974

20160235862

2016-08-18

Vaults engineered for hydrophobic drug delivery

#1975

20160230163

2016-08-11

Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities

#1976

20160229901

2016-08-11

Interleukin-2 fusion proteins and uses thereof

#1977

20160229896

2016-08-11

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses

#1978

20160222080

2016-08-04

MULTIPLE TARGET T CELL RECEPTOR

#1979

20160215039

2016-07-28

AGENTS AND METHODS BASED ON THE USE OF THE EDA DOMAIN OF FIBRONECTIN

#1980

20160215025

2016-07-28

Pseudomonas exotoxin a with less immunogenic T cell and/or B cell epitopes

#1981

20160208021

2016-07-21

Molecular constructs with targeting and effector moieties

#1982

20160208020

2016-07-21

Peptide core-based multi-arm linkers

#1983

20160208015

2016-07-21

Human monoclonal antibodies specific for glypican-3 and use thereof

#1984

20160208012

2016-07-21

Compositions and methods for treatment of cancer

#1985

20160206754

2016-07-21

Molecular constructs for treating tumors

#1986

20160200833

2016-07-14

Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

#1987

20160200824

2016-07-14

Anti CD30 chimeric antigen receptor and its use

#1988

20160200796

2016-07-14

Fusion protein comprising albumin and retinol-binding protein

#1989

20160194404

2016-07-07

Compositions and methods for treatment of cancer

#1990

20160185862

2016-06-30

Chimeric antigen receptor and methods of use thereof

#1991

20160185838

2016-06-30

Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor

#1992

20160184415

2016-06-30

Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens

#1993

20160184407

2016-06-30

Class of therapeutic protein based molecules

#1994

20160184394

2016-06-30

Adeno-associated virus virions with variant capsid and methods of use thereof

#1995

20160177286

2016-06-23

GLA-DOMAINLESS FACTOR X

#1996

20160177284

2016-06-23

CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS

#1997

20160177276

2016-06-23

SIRP-α immunoglobulin fusion proteins

#1998

20160176980

2016-06-23

T-cell redirecting bispecific antibodies for treatment of disease

#1999

20160175389

2016-06-23

Peptides having specificity for the lungs

#2000

20160168260

2016-06-16

Method of treating cancer with an EGFR targeted immunomodulatory fusion protein

#2001

20160166657

2016-06-16

Factor IX polypeptides and methods of use thereof

#2002

20160159920

2016-06-09

Coiled coil immunoglobulin fusion proteins and compositions thereof

#2003

20160159907

2016-06-09

Compositions and methods for treatment of cancer

#2004

20160159878

2016-06-09

NOGO Receptor Antagonists

#2005

20160159875

2016-06-09

Targeting of human interferon antagonists

#2006

20160158359

2016-06-09

Methods and compositions for adoptive cell therapy

#2007

20160152711

2016-06-02

DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES

#2008

20160152680

2016-06-02

Targeted therapeutic proteins

#2009

20160152676

2016-06-02

Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions

#2010

20160151490

2016-06-02

Methods and compositions for treating cancer

#2011

20160151466

2016-06-02

Botulinum neurotoxins with modified light chain specificity and methods for producing same

#2012

20160137709

2016-05-19

ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION

#2013

20160129086

2016-05-12

Interferon lambda-antibody complexes

#2014

20160122766

2016-05-05

Methods and compositions for reducing immunosupression by tumor cells

#2015

20160122731

2016-05-05

Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses

#2016

20160122412

2016-05-05

Composition comprised of antigen linked to a TNF superfamily ligand

#2017

20160122410

2016-05-05

Interferon alpha 2B variants

#2018

20160115468

2016-04-28

Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein

#2019

20160115234

2016-04-28

Anti-GPIIB/IIIA antibodies or uses thereof

#2020

20160115214

2016-04-28

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

#2021

20160108133

2016-04-21

Methods and compositions for treatment of Pompe disease

#2022

20160106862

2016-04-21

Re-directed immunotherapy

#2023

20160106819

2016-04-21

Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

#2024

20160106817

2016-04-21

Treatment for BK polyomavirus infection

#2025

20160102127

2016-04-14

TARGETED MODULATION OF MACROPHAGES

#2026

20160097044

2016-04-07

Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus

#2027

20160096902

2016-04-07

Anti-CD19 scFv (FMC63) polypeptide

#2028

20160096892

2016-04-07

Treatment of cancer using a CD33 chimeric antigen receptor

#2029

20160095917

2016-04-07

Dps fusion proteins for use in vaccines and diagnostics

#2030

20160089451

2016-03-31

METHODS AND COMPOSITIONS FOR TREATMENT OF FORBES-CORI DISEASE

#2031

20160083477

2016-03-24

Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function Proteins

#2032

20160083450

2016-03-24

HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS

#2033

20160083446

2016-03-24

Chimeric leptin polypeptide and method of using the same

#2034

20160075784

2016-03-17

CS1-specific chimeric antigen receptor engineered immune effector cells

#2035

20160074448

2016-03-17

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

#2036

20160068601

2016-03-10

Treatment of cancer using a CD123 chimeric antigen receptor

#2037

20160068598

2016-03-10

ANTI-CD19 COMPOSITIONS AND METHODS FOR TREATING CANCER

#2038

20160068569

2016-03-10

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

#2039

20160060316

2016-03-03

Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle

#2040

20160058857

2016-03-03

Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides

#2041

20160058792

2016-03-03

Methods and compositions of treating autoimmune diseases

#2042

20160052976

2016-02-25

MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS

#2043

20160046724

2016-02-18

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

#2044

20160046700

2016-02-18

Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12

#2045

20160045599

2016-02-18

Devices, systems and methods for optogenetic modulation of action potentials in target cells

#2046

20160039904

2016-02-11

STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS

#2047

20160039888

2016-02-11

IMMUNOGENIC COMPOSITION COMPRISING ALPHA-HEMOLYSIN OLIGOPEPTIDES

#2048

20160030479

2016-02-04

Modified T lymphocytes comprising an inducible caspase and methods of apoptosis

#2049

20160024192

2016-01-28

MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS

#2050

20160024170

2016-01-28

Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences

#2051

20160022792

2016-01-28

ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES

#2052

20160017047

2016-01-21

CD20-binding immunotoxins for inducing cellular internalization and methods using same

#2053

20160017014

2016-01-21

Peptide having 5 linked CTL epitopes

#2054

20160017004

2016-01-21

METHODS AND THERAPEUTICS COMPRISING LIGAND-TARGETED ELPs

#2055

20160015827

2016-01-21

Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof

#2056

20160009824

2016-01-14

TETRAVALENT BISPECIFIC ANTIBODIES

#2057

20160009813

2016-01-14

Effective generation of tumor-targeted T cells derived from pluripotent stem cells

#2058

20160008480

2016-01-14

Fusion protein comprising targeting moiety, cleavage site, and cell membrane penetrating domain, and use thereof

#2059

20160008452

2016-01-14

Vault compositions for immunization

#2060

20160000930

2016-01-07

Methods and compositions for targeting adipose cells in mammals

#2061

20150376568

2015-12-31

Method of introducing a toxin or dye into mammalian pluripotent cells using rBC2LCN

#2062

20150376256

2015-12-31

Glucagon/GLP-1 receptor co-agonists

#2063

20150376253

2015-12-31

Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon

#2064

20150374860

2015-12-31

Treatment of metastatic tumors

#2065

20150368628

2015-12-24

Deimmunized gelonin molecules and therapies

#2066

20150366991

2015-12-24

Antigen-Specific T cell redirectors

#2067

20150361163

2015-12-17

METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE

#2068

20150353642

2015-12-10

Fusion proteins that facilitate cancer cell destruction

#2069

20150344586

2015-12-03

Disulfide-linked multivalent MHC class I comprising multi-function proteins

#2070

20150344570

2015-12-03

Heterodimerized polypeptide

#2071

20150344525

2015-12-03

Dual-targeted therapeutic peptide for nasopharyngeal carcinoma, nanoparticles carrying same and uses thereof

#2072

20150342993

2015-12-03

Compositions and methods for immunotherapy

#2073

20150337025

2015-11-26

Use of fusion protein

#2074

20150329847

2015-11-19

Fusion protein comprising granzyme B and use thereof

#2075

20150315247

2015-11-05

High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy

#2076

20150314011

2015-11-05

Amphipathic peptide

#2077

20150313965

2015-11-05

Combination of lenalidomide and polypeptide construct, and uses thereof

#2078

20150307623

2015-10-29

Chimeric antigen receptors

#2079

20150307560

2015-10-29

Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof

#2080

20150291979

2015-10-15

NOVEL PSEUDOTYPED LENTIVIRAL PARTICLES AND THEIR USE IN THE IN VITRO TARGETED TRANSDUCTION OF UNDIFFERENTIATED PLURIPOTENT HUMAN EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS

#2081

20150291665

2015-10-15

Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response

#2082

20150290305

2015-10-15

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases

#2083

20150290304

2015-10-15

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl tRNA synthetases

#2084

20150284454

2015-10-08

ANTI-SERUM ALBUMIN BINDING VARIANTS

#2085

20150284452

2015-10-08

ANTIMICROBIAL COMPOSITIONS

#2086

20150283260

2015-10-08

Antibody-light fusion products for cancer therapeutics

#2087

20150274827

2015-10-01

Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor

#2088

20150273010

2015-10-01

HIGH-THROUGHPUT ASSAYS FOR HIV-1 ENVELOPE MATURATION AND NOVEL PEPTIDE INHIBITORS AGAINST HIV-1

#2089

20150266936

2015-09-24

Conjugated knottin mini-proteins containing non-natural amino acids

#2090

20150259431

2015-09-17

COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES

#2091

20150259418

2015-09-17

Microtubule-modifying compound

#2092

20150250868

2015-09-10

Re-directed immunotherapy

#2093

20150246956

2015-09-03

Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

#2094

20150239979

2015-08-27

Compositions and methods

#2095

20150238577

2015-08-27

Chimeric polypeptides and their use in bacterial decolonization

#2096

20150232547

2015-08-20

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

#2097

20150231239

2015-08-20

Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing

#2098

20150231216

2015-08-20

Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

#2099

20150225702

2015-08-13

Adeno-associated virus virions with variant capsid and methods of use thereof

#2100

20150225483

2015-08-13

Targeted TGFβ inhibitors